Paradigm Biocapital Advisors’s Vaxcyte PCVX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$124M	Sell	2,127,852 -2,665,168	-56%	-$145M	2.32%	15
2026 Q1	$279M	Buy	4,793,020 +725,000	+18%	+$39.4M	5.69%	4
2025 Q4	$188M	Buy	4,068,020 +283,265	+7%	+$12.7M	4.79%	8
2025 Q3	$136M	Buy	3,784,755 +411,918	+12%	+$13.6M	3.88%	6
2025 Q2	$110M	Buy	3,372,837 +1,676,356	+99%	+$55M	4.68%	6
2025 Q1	$64.1M	Buy	1,696,481 +273,694	+19%	+$21.9M	2.93%	10
2024 Q4	$116M	Buy	1,422,787 +795,055	+127%	+$78.9M	4.05%	8
2024 Q3	$71.7M	Buy	627,732 +530	+0.1%	+$47.8K	2.43%	12
2024 Q2	$47.4M	Sell	627,202 -612,793	-49%	-$41.7M	1.81%	18
2024 Q1	$84.7M	Buy	+1,239,995	New	+$85.9M	2.98%	16

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Paradigm Biocapital Advisors's PCVX Position: Q2 2026 in Review

Paradigm Biocapital Advisors reduced its Vaxcyte (PCVX) stake by 56% in Q2 2026, selling an estimated $145M and leaving 2,127,852 shares worth $124M. The position accounts for 2.32% of the portfolio, ranked #15.

Paradigm Biocapital Advisors first reported a position in PCVX in Q1 2024 and has held it in 10 quarters since. The position peaked at $279M in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Paradigm Biocapital Advisors held 2,127,852 shares of Vaxcyte worth $124M as of Q2 2026.
Paradigm Biocapital Advisors sold 2,665,168 Vaxcyte shares in Q2 2026, an estimated $145M.
Vaxcyte made up 2.32% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #15 holding.
Paradigm Biocapital Advisors first reported a position in Vaxcyte in Q1 2024 and has held it in 10 quarters since.
Paradigm Biocapital Advisors's Vaxcyte position peaked at $279M in Q1 2026.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.